
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is a leading global pharmaceutical company with a strong focus on prescription drugs and vaccines, which account for the majority of their sales. Their strong presence in emerging markets and successful products such as Prevnar 13 and Eliquis contribute to their positive outlook. Upcoming data readouts in oncology and obesity, as well as potential NPV accretion from their pivotal tafamidis bench trial, could provide upside for the stock. However, risks include significant patent expirations in 2026-2028 and potential challenges to their key patents. Overall, Pfizer's proactive capital deployment and growth initiatives balance out these risks and support their current valuation.
Bears say
Pfizer is facing a number of headwinds that could negatively impact its stock. First, the company has significant exposure to emerging markets, which may be more volatile and present challenges with issues like access to medicines and regulatory hurdles. Additionally, Pfizer has a high concentration of upcoming patent expirations, leading to a potential earnings trough in 2028-2029. Furthermore, the company's recent track record in M&A has been mixed, creating uncertainty around its ability to drive growth through acquisitions. Overall, these factors contribute to a negative outlook for Pfizer's stock.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares